249 related articles for article (PubMed ID: 21303974)
1. Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity.
Inoue S; Ding H; Portilla-Arias J; Hu J; Konda B; Fujita M; Espinoza A; Suhane S; Riley M; Gates M; Patil R; Penichet ML; Ljubimov AV; Black KL; Holler E; Ljubimova JY
Cancer Res; 2011 Feb; 71(4):1454-64. PubMed ID: 21303974
[TBL] [Abstract][Full Text] [Related]
2. Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer.
Inoue S; Patil R; Portilla-Arias J; Ding H; Konda B; Espinoza A; Mongayt D; Markman JL; Elramsisy A; Phillips HW; Black KL; Holler E; Ljubimova JY
PLoS One; 2012; 7(2):e31070. PubMed ID: 22355336
[TBL] [Abstract][Full Text] [Related]
3. Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer.
Ding H; Helguera G; Rodríguez JA; Markman J; Luria-Pérez R; Gangalum P; Portilla-Arias J; Inoue S; Daniels-Wells TR; Black K; Holler E; Penichet ML; Ljubimova JY
J Control Release; 2013 Nov; 171(3):322-9. PubMed ID: 23770212
[TBL] [Abstract][Full Text] [Related]
4. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
5. Polymalic acid-based nano biopolymers for targeting of multiple tumor markers: an opportunity for personalized medicine?
Ljubimova JY; Ding H; Portilla-Arias J; Patil R; Gangalum PR; Chesnokova A; Inoue S; Rekechenetskiy A; Nassoura T; Black KL; Holler E
J Vis Exp; 2014 Jun; (88):. PubMed ID: 24962356
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of brain tumor growth by intravenous poly (β-L-malic acid) nanobioconjugate with pH-dependent drug release [corrected].
Ding H; Inoue S; Ljubimov AV; Patil R; Portilla-Arias J; Hu J; Konda B; Wawrowsky KA; Fujita M; Karabalin N; Sasaki T; Black KL; Holler E; Ljubimova JY
Proc Natl Acad Sci U S A; 2010 Oct; 107(42):18143-8. PubMed ID: 20921419
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
8. Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(beta-L-malic acid).
Fujita M; Lee BS; Khazenzon NM; Penichet ML; Wawrowsky KA; Patil R; Ding H; Holler E; Black KL; Ljubimova JY
J Control Release; 2007 Oct; 122(3):356-63. PubMed ID: 17630012
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes.
Jain R; Rawat A; Verma B; Markiewski MM; Weidanz JA
J Natl Cancer Inst; 2013 Feb; 105(3):202-18. PubMed ID: 23300219
[TBL] [Abstract][Full Text] [Related]
10. HER2/neu antisense targeting of human breast carcinoma.
Roh H; Pippin JA; Green DW; Boswell CB; Hirose CT; Mokadam N; Drebin JA
Oncogene; 2000 Dec; 19(53):6138-43. PubMed ID: 11156527
[TBL] [Abstract][Full Text] [Related]
11. The vitamin E analog, alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancer.
Hahn T; Bradley-Dunlop DJ; Hurley LH; Von-Hoff D; Gately S; Mary DL; Lu H; Penichet ML; Besselsen DG; Cole BB; Meeuwsen T; Walker E; Akporiaye ET
BMC Cancer; 2011 Nov; 11():471. PubMed ID: 22044845
[TBL] [Abstract][Full Text] [Related]
12. Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells.
Baumann J; Wong J; Sun Y; Conklin DS
BMC Cancer; 2016 Jul; 16():551. PubMed ID: 27464732
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
14. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.
Cao Y; Marks JW; Liu Z; Cheung LH; Hittelman WN; Rosenblum MG
Oncogene; 2014 Jan; 33(4):429-39. PubMed ID: 23376850
[TBL] [Abstract][Full Text] [Related]
15. Targeting HER2: recent developments and future directions for breast cancer patients.
Wang SC; Zhang L; Hortobagyi GN; Hung MC
Semin Oncol; 2001 Dec; 28(6 Suppl 18):21-9. PubMed ID: 11774202
[TBL] [Abstract][Full Text] [Related]
16. Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells.
Tari AM; Lim SJ; Hung MC; Esteva FJ; Lopez-Berestein G
Oncogene; 2002 Aug; 21(34):5224-32. PubMed ID: 12149644
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral heterogeneity impacts the response to anti-neu antibody therapy.
Song H; Kim TO; Ma SY; Park JH; Choi JH; Kim JH; Kang MS; Bae SK; Kim KH; Kim TH; Seo SK; Choi IW; Song GA; Mortenson ED; Fu YX; Park S
BMC Cancer; 2014 Sep; 14():647. PubMed ID: 25179116
[TBL] [Abstract][Full Text] [Related]
18. Toxicity and efficacy evaluation of multiple targeted polymalic acid conjugates for triple-negative breast cancer treatment.
Ljubimova JY; Portilla-Arias J; Patil R; Ding H; Inoue S; Markman JL; Rekechenetskiy A; Konda B; Gangalum PR; Chesnokova A; Ljubimov AV; Black KL; Holler E
J Drug Target; 2013 Dec; 21(10):956-967. PubMed ID: 24032759
[TBL] [Abstract][Full Text] [Related]
19. Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway.
Way TD; Kao MC; Lin JK
J Biol Chem; 2004 Feb; 279(6):4479-89. PubMed ID: 14602723
[TBL] [Abstract][Full Text] [Related]
20. Quantitative analysis of PMLA nanoconjugate components after backbone cleavage.
Ding H; Patil R; Portilla-Arias J; Black KL; Ljubimova JY; Holler E
Int J Mol Sci; 2015 Apr; 16(4):8607-20. PubMed ID: 25894227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
